by

For more information about Yacella®, please click here for the prescribing information.

Yacella® – A lower cost,1–3 bioequivalent alternative to Yasmin®4,5

  • Yacella® is a monophasic combined oral contraceptive (COC), pill which contains 0.03 mg ethinylestradiol and 3 mg drospirenone3
  • Yacella® contains the same active ingredients and has demonstrated bioequivalence to Yasmin®, therefore, following appropriate patient assessment and review, it may be prescribed in place of Yasmin®3–6
  • Each pack of Yacella® contains 3 x blister strips of 21 tablets for 3 cycles of contraceptive cover7
Yacella-0.03mg-3mg-Tablets_HB
Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.
Summary of Product Characteristics and Patient Information Leaflet
The links below will take you to the electronic Medicines Compendium (eMC). By clicking the links below you will leave the Morningside Healthcare Contraceptives website and be re-directed to an external site; Morningside Healthcare is not responsible for the content on external websites.

Please click here to access the Summary of Product Characteristics

Please click here to access the Patient Information Leaflet

Risk Minimisation Materials
The links below will take you to the electronic Medicines Compendium (eMC). By clicking the links below you will leave the Morningside Healthcare Contraceptives website and be re-directed to an external site; Morningside Healthcare is not responsible for the content on external websites.

Please click here to access the Prescriber Checklist, Patient Alert Card, Important Information for Women leaflet and a letter confirming formulation/format changes

Please click here to access a warning letter concerning the thromboembolism risk of combined hormonal contraceptives

Additional Prescriber Resources
Whether your patient is starting the pill for the first time, or you are talking to them about changing from their current brand of contraceptive to Yacella®, it can be useful to have information and materials to hand to counsel patients. The following assets can be downloaded/edited at your discretion for use during a consultation:

By clicking the link below you will leave the Morningside Healthcare Contraceptives website and be re-directed to an external site; Morningside Healthcare is not responsible for the content on external websites.

The full NICE Clinical Knowledge Summary for contraceptive prescribing for combined oral contraceptives, including UK Medical Eligibility Criteria may be found here.

References

  1. UK drug tariff (Accessed April 2024)
  2. NHS dm+d. Actual Medicinal Product (AMP) Yasmin tablets (Bayer PLC). Available at: https://dmd-browser.nhsbsa.nhs.uk/amp/view/8433 (accessed January 2024);
  3. NHS dm+d. Actual Medicinal Product (AMP) Yacella 0.03mg/3mg tablets (Morningside Healthcare Ltd). Available at: https://dmd-browser.nhsbsa.nhs.uk/amp/view/118813 (accessed January 2024);
  4. MHRA. UK PAR Yacella 0.03 mg/3 mg tablets. December 2015. Available at: https://mhraproductsproduction.blob.core.windows.net/docs/da60a925891cddb6949eeca3625262f534a3a163 (accessed January 2024);
  5. Bayer PLC. Yasmin PIL. Available at: https://www.medicines.org.uk/emc/files/pil.1607.pdf (accessed January 2024);
  6. Bayer PLC. Yasmin film-coated tablets 0.03mg/3mg. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1607/smpc (accessed January 2024);
  7. NHS dm+d. Actual Medicinal Product Pack (AMPP) Yacella 0.03mg/3mg tablets (Morningside Healthcare Ltd) 63 tablet 3 x 21 tablets. Available at: https://dmd-browser.nhsbsa.nhs.uk/ampp/view/13667 (accessed January 2024).

Yasmin® chosen as a comparator as it is the license reference product for Yacella®.4,5

Filed Under: hcp, hcp-yacella